Media Coverage header image

Media Coverage

Advanced Search
  • 11212023
    NJBIZ

    Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.

  • 11172023
    Clinical Lab Products

    For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.

  • 11162023
    NeurologyLive

    In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.

  • 11102023
    ROI-NJ

    Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.

  • 11082023
    Today's Clinical Lab

    Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.

  • 11072023
    KATV-TV (Little Rock, AR)

    Alzheimer's disease is the most common form of dementia and affecting about 6 million people in the United States. A simple blood test is providing a new way for doctors to detect the potential risk of Alzheimer's disease in its early stages. Here to talk about this groundbreaking new approach is a board-certified neurologist and medical director of neurology at Quest Diagnostics.

  • 10252023
    Inside Precision Medicine

    Diagnostics firm Diadem said Wednesday that it has licensed exclusive US rights to its AlzoSure Predict Alzheimer's blood test to Quest Diagnostics. Under the agreement, Quest can develop, validate, and market the assay, which is intended to identify individuals likely to progress to Alzheimer's disease, as a laboratory-developed test in the US. AlzoSure Predict measures a variant of the p53 protein that has been linked to Alzheimer's disease.

  • 10242023
    Reuters

    Laboratory operator Quest Diagnostics on Tuesday raised its full-year sales forecast after beating third-quarter expectations for revenue and profit, buoyed by a recovery in routine testing. The company raised its full-year net sales forecast to $9.19 billion to $9.24 billion, from its previous expectations of $9.12 billion to $9.22 billion. Sales from Quest's base business, which includes a range of diagnostic tests for allergies, chronic diseases and cancer, rose 4.6% to $2.27 billion in the third quarter. That extends a rebound in routine health check-ups delayed due to pandemic-related lockdowns for diagnostic firms like Quest and eases the blow from plunging demand for COVID-19 tests.

  • 10052023
    360Dx

    Dialysis company Neway said Thursday that it has entered a strategic lab services arrangement with Quest Diagnostics to speed dialysis lab testing and reduce testing costs for patients with end-stage renal disease (ESRD). Under the terms of the agreement, Neway will use Quest's lab network to provide local testing services, enabling next-day results while also reducing sample transportation costs.

  • 09252023
    Forbes

    Self-service has seen incredible growth in recent years, and this is just the beginning. 81% of customers want more self-service options. Here are 20 of the best examples of self-service:

    13. Quest Diagnostics Cuts Wait Time with Kiosks
    Medical lab company Quest Diagnostics cuts wait times with interactive kiosks that patients can use to check in, upload insurance information, and make payments. The devices help patients be seen faster, allowing medical staff to spend more time working with patients and less on administrative tasks.

  • 09142023
    Westchester County Business Journal

    Stamford-based Americares is partnering with Quest Diagnostics to provide 10 clinics across the U.S. with no-cost diagnostic services for one year as a means of increasing access to care for low-income, uninsured and underinsured patients.

  • 09062023
    Patch.com

    Rutgers and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured patients of the university’s Health Outreach Practice Experience (H.O.P.E.) Clinic in Plainfield. Resources from the Quest Diagnostics Foundation will enable the clinic to double its capacity by providing primary care services for a second day of the week.

  • 08312023
    Medical Device Network

    Quest Diagnostics has secured breakthrough device designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay, from the US Food and Drug Administration (FDA). The test is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in the serum of humans. Quest also expanded collaboration with Sarepta to develop complementary diagnostics for Sarepta's gene therapies.

  • 08282023
    360Dx

    Researchers from Quest Diagnostics and collaborators have found that changes in levels of the cardiovascular risk marker free myeloperoxidase (MPO) appear correlated with an individual's overall mortality risk. The finding, described in a study published last month in PLOS One, indicate that longitudinal measurement of MPO could help physicians assess patients' mortality risk and response to interventions.

  • 08102023
    Urology Times

    Quest Diagnostics has partnered with Envision Sciences to commercially launch a novel prostate cancer biomarker test to help in identifying patients with more aggressive forms of the disease, Quest Diagnostics and the University of South Australia announced in separate news releases.1,2"Our goal for this innovative prostate biomarker test is to improve the accuracy of grading prostate cancer biopsies.

  • 08082023
    WIRED

    Made by New Jersey–based Quest Diagnostics, the $399 test can be purchased online by anyone age 18 and older in most US states, who then must go to a Quest clinic for a blood draw. The test measures blood levels of a protein called amyloid beta. As a person ages, amyloid beta tends to accumulate in the brain and can eventually form plaques, which are linked to Alzheimer’s disease. It’s thought that these clumps build up many years before memory loss and confusion appear.

  • 08032023
    Safety+Health

    For decades, employers have relied on workplace drug testing as a risk mitigation tool to effectively deter drug use and help prevent costly incidents. However, with cannabis legalization expanding, so is its use and acceptance. The connection between increasing cannabis availability and increased use of cannabis at work creates significant risks and costs for employers. So, why isn’t it possible to determine impairment from cannabis yet? “The main point many people fail to realize is that alcohol had decades, literally decades, of study to get to an impairment standard,” toxicology and workforce drug testing expert Barry Sample, of Quest Diagnostics, explains.

  • 07312023
    Healthline

    Quest Diagnostics launched on July 31 a direct-to-consumer blood test to detect abnormal levels of beta-amyloidTrusted Source, a protein involved in Alzheimer’s disease that can show up in the brain years before symptoms arise. The first-of-its-kind test, called AD-Detect, will cost $399, plus a $13 physician service fee. The technology is the same as the AD-Detect Amyloid Beta 42/40 Ratio blood test launched by the company in early 2022, which is available with a doctor’s order.

  • 07262023
    Reuters

    Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pandemic. Non-COVID testing at companies such as Quest and rival Labcorp was hit as people delayed routine health check-ups following pandemic-led lockdowns, but that demand has now started to normalize while COVID testing sales have fallen.

  • 07172023
    Lab Pulse

    An analysis of 462 million lipid test results has shown mean total cholesterol levels exceed the target in seven of the 17 studied countries. Writing in the European Heart Journal, members of the Global Diagnostics Network (GDN) describe the evaluation of lipid test data generated by nine clinical laboratories working in 17 countries. Seth Martin, lead author of the study and professor of medicine at Johns Hopkins University School of Medicine, discussed the analysis and the potential implications of its findings in a statement from Quest Diagnostics, the company that leads the GDN.

  • 07062023
    ROI-NJ

    Quest Diagnostics said Thursday that women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com. The Proov Confirm PdG test is the first and only FDA-cleared PdG (progesterone metabolite) home test kit to confirm successful ovulation. Through a collaboration between Secaucus-based Quest and Proov, the test is the first women’s health test from a third-party manufacturer available through questhealth.com.

  • 06292023
    CNN

    For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study. A study published Thursday in the CDC’s Morbidity and Mortality Weekly Report reveals how deep the disparities in access to hepatitis C therapies have become. Using testing data from Quest Diagnostics, researchers were able to track the fates of 1 million Americans diagnosed with hepatitis C infections in the decade since the most effective drugs were introduced. Overall, just 1 in 3 were cured over that time period.

  • 06222023
    NJBIZ

    Quest Diagnostics has finalized its previously announced acquisition of Baltimore-based Haystack Oncology, the Secaucus clinical laboratory company said June 21. Under the terms of the deal unveiled April 27, Quest said it would pay Haystack $300 million in cash at closing, net of cash acquired, and up to an additional $150 million based on future performance milestones.

  • 06142023
    SHRM HR News

    The ongoing flurry of marijuana legislation, court cases and cannabis-based products makes it difficult for HR professionals to craft policies that meet their company's drug-testing needs. The significant differences in state-by-state rules, definitions and interpretations of recreational and medical marijuana products have only added to the potential confusion. People in U.S. states that legalized recreational cannabis use it 20 percent more frequently than people in other states, according to a 2022 study in the journal Addiction. Nationwide, 4.4 percent of workers failed tests that Quest Diagnostics processed in 2020, up from 3.5 percent in 2012. The rate was slightly higher in states where adults are allowed to buy recreational marijuana.

  • 06082023
    Clinical Lab Products

    Alzheimer’s disease is devastating to both patients and their families and caregivers. And while there are better means to diagnosis Alzheimer’s today, in many cases, it is only determined after symptoms become apparent. Today, about 6 million Americans are struggling with Alzheimer’s disease and other dementias. That number is expected to more than double by mid-century. In a wide-ranging discussion about the disease with CLP, Michael Racke, MD, medical director of neurology for Quest Diagnostics, outlines a new test that can help spot Alzheimer’s and other dementias earlier, what that means for treatment options, and how it could help transform Alzheimer’s into a manageable condition and not a death sentence for patients.

  • 05292023
    The Pathologist

    Dr. Mark Kruzel, MD, MBA, Associate Medical Director of Oncology at Quest Diagnostics, shares how the pathology-oncology care team can work together more closely to leverage the true power of precision therapies.

  • 05182023
    CBS News

    As the number of cannabis-friendly states across the U.S. has grown, so, too, has the drug's usage among American workers. An annual analysis from Quest Diagnostics medical lab and testing company shows the percentage of general U.S. employees, who tested positive for cannabis in 2022 reached the highest level ever recorded by Quest, which began analyzing annual workplace drug testing data in 1988.

  • 05182023
    The Wall Street Journal

    As legal marijuana expands in the U.S., a record share of workers is testing positive for the substance in workplace drug screening. Overall drug use among workers tested by employers generally held steady last year, according to an annual tally from Quest Diagnostics, one of the country’s largest drug-testing laboratories. In drug tests given to workers after accidents on the job, marijuana positives rose sharply last year, hitting the highest level in a quarter-century.

  • 05122023
    Clinical Lab Products

    Quest Diagnostics announced nationwide availability of the RestoreU Dementia Panel, a risk assessment and care plan AI-powered test service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.

  • 05112023
    USA Today

    Thursday marks the end of the public health emergency in the United States, more than three years after it was first declared to combat the novel coronavirus by unlocking powerful tools to detect and contain the emerging threat. While it closes a chapter in history, health experts point out the COVID-19 pandemic is not yet over as the virus continues to claim about 1,000 lives each week, according to the Centers for Disease Control and Prevention. Quest Diagnostics, one of the largest lab companies in the country, said labs will continue to provide COVID-19 services and tests, but “access to, fees and reimbursement for COVID-19 testing will change after the (public health emergency) expires.”

  • 05082023
    Fox News

    With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a company called uMETHOD to create RestoreU, a tool that uses artificial intelligence to help physicians create personalized care plans for patients with Alzheimer’s and other types of dementia. "Dementia is what’s called a complex disease," CEO Vik Chandra, co-founder and CEO of uMETHOD Health in Cary, North Carolina, said in an interview with Fox News Digital. Through a partnership with Quest Diagnostics, uMETHOD has rolled out its AI service to physicians, who can order the service through the patient’s electronic health record. Once the physician orders the service, it triggers the exchange of extensive information between the doctor's electronic health record systems and Quest Diagnostics, Chandra explained.

  • 04272023
    Fierce Biotech

    Quest Diagnostics is hoping it’s found a winner in Haystack Oncology, with a $450 million bet on the cancer-focused blood test startup. The clinical testing giant plans to acquire Baltimore-based Haystack for its technology to detect minimal residual disease by catching the early signs of a solid tumor’s recurrence by sifting out small pieces of cancer DNA floating in the bloodstream.

  • 04272023
    Reuters

    Quest Diagnostics Inc posted first-quarter profit ahead of Wall Street estimates on Thursday as its base business helped offset a fall in COVID-19 test kits sales. Demand for routine diagnostic tests has picked up as an increasing number of people return to the healthcare system for routine care after delaying care during the pandemic.

  • 04202023
    Managed Healthcare Executive

    For health plans to try to tackle the complex issue of food insecurity and its overall impact and consequences, it takes another step, but the outcomes are worth it. Let’s look at Pack Health’s Better Food for Better Health (BFBH) to demonstrate. Our food insecurity solution combines biweekly food box delivery, food security screenings and digital health coaching into an in-depth, but practical, program for those experiencing food insecurity. BFBH presents a valuable opportunity for health plans, health systems, and employers to support vulnerable populations experiencing food insecurity.

  • 04172023

    Secaucus-based Quest Diagnostics and NewYork-Presbyterian on Monday announced that Quest has completed its previously announced acquisition of select assets of the laboratory services business of NewYork-Presbyterian. Financial details of the transaction were not disclosed.

  • 04122023
    Newsweek

    Because trust plays a big part in customers' decisions about what to buy, employees' decisions about where to work and investors decisions about whether to invest, Newsweek, in collaboration with market research partner Statista, is proud to introduce our second annual listing of the Most Trustworthy Companies in America. This year we've listed 700 U.S. companies in 23 industries according to their evaluations by U.S. customers, employees and investors.

    11: Health Care & Life Sciences / Quest Diagnostics / New Jersey / Public Company

  • 04042023
    FierceHealthcare

    Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among patients by making the testing more accessible. Its Advanced Specialized Transplant Services now include customized educational resources for patients, expedited transport and processing of tests and 5,000 mobile phlebotomists for at-home specimen collection.

  • 03272023
    NJBIZ

    Times like these demonstrate the importance of the health care industry to New Jersey’s economy. The sector’s impact has been well documented in dollar terms over the years and officials at levels profess to recognize the critical role health care companies play – not only in providing care but also keeping the state in business. This year’s Health Care Power 50 list reflects another side of the economic story.

  • 03232023
    ROI-NJ

    Quest Diagnostics on Wednesday announced support for a new program with Sesame Workshop, the nonprofit educational organization behind “Sesame Street.” The resources launched aim to address health and well-being inequities among young children, particularly in low-income, rural and marginalized communities.

  • 03222023
    Lab Pulse

    Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.

  • 03162023
    Science

    Doctors and drug companies are also warming to the medical possibilities of ceramides. Later this year, lab testing giant Quest Diagnostics will start to offer the analysis, potentially making it available to many more patients.

  • 03132023
    Health News

    Diagnosing Alzheimer’s disease before symptoms develop may soon be as simple as getting a blood test. New blood tests for certain biomarkers show promise, providing physicians an alternative to expensive scans or invasive spinal taps to make a diagnosis. Quest AD-Detect: Introduced by Quest Diagnostics, this blood test also measures beta-amyloid proteins in your blood to determine your risk for developing Alzheimer’s disease. It does not determine if you have any genetic biomarkers for the disease. The test became available in May 2022, with a cost of $500. There is limited coverage by some health plans.

  • 03062023
    NJBIZ

    Although automation and artificial intelligence have long been recognized as a way to improve operational efficiency in clinical laboratories, an industry-wide staffing shortage is creating an added motivation to incorporate more technology. At Secaucus-based Quest Diagnostics, it’s just one of many market forces that is shaping the company’s post-pandemic business strategy.

  • 03012023
    Fortune

    Medical testing center operator Quest Diagnostics Inc. said that it has begun using a highly automated microbiology lab system that leverages AI to analyze samples. CEO Jim Davis mentioned the platform in the company’s earnings call when he was talking about ways in which it’s trying to counter “significant inflation and wage pressures.”

  • 02212023
    AARP

    Do you know your blood type? There’s a good chance that you don’t. More Americans know their horoscope sign (66 percent) than their blood type (51 percent), according to a survey published this year by laboratory company Quest.

  • 02142023
    Crain's New York

    Quest Diagnostics, a nationwide medical testing company, will acquire some lab services from New York-Presbyterian in the coming months, the organizations announced Tuesday. The deal will allow physicians affiliated with New York-Presbyterian who work outside of the hospital to send diagnostics for processing to Quest’s laboratory in Clifton, New Jersey. The organizations said they expect to complete the deal in the second quarter of this year, pending regulatory approvals. This acquisition will not affect all testing services. New York-Presbyterian will keep anatomical pathology testing in house along with other diagnostics that require a quick turnaround time, the organizations said.

  • 02022023
    Becker's Hospital Review

    While tech companies Apple, Amazon and Microsoft took top spots on the 2023 "World's Most Admired Companies" list released by Fortune on Feb. 1, healthcare-related companies were also included. The list, a partnership between Fortune and global management consulting firm Korn Ferry, is based on an analysis of 645 companies in 27 countries. 34 healthcare companies are among the Most Admired Companies in their industries.

  • 01252023
    WABI-TV/CBS

    EJ Hikel from Northern Light Health and Brandy Dow from Quest Diagnostics talk about blood donation.

  • 01232023
    Medical Laboratory Observer

    Ten years ago, drug overdoses claimed nearly 42,000 lives annually in the United States. By the end of 2021, that number climbed to nearly 108,000. Today, the drug crisis shows no signs of abating, and remains largely fueled by increased access to illicit drugs as well as barriers to healthcare access exacerbated by the COVID-19 pandemic. For the last decade, Quest Diagnostics, through its Health Trends program, has examined insights gleaned from results of our large volume of clinical drug tests, with a goal of empowering better patient care, population health management and informing public health policy.

  • 01232023
    NJBIZ

    Anyone who has had medical tests performed likely knows about Quest Diagnostics. The Secaucus-based company is perhaps the most prominent testing company in the world. For this edition of NJBIZ Conversations, Wendi Mader – Quest’s vice president of the commercial employer channel – talks about what it was like to play that role and discusses how she and her staff continue to help businesses identify and mitigate health risks faced by their employees.

Show 5102550100 per page